Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab, Dabrafenib, and Tislelizumab in BRAF-mutated Advanced Colorectal Cancer
NCT05963087Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and tislelizumab in colorectal cancer (CRC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate at 12 months. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
dabrafenib + trametinibtislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05963087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963087.